The global anti-obesity drugs market size reached US$ 2.0 Billion in 2022. Looking forward, the publisher expects the market to reach US$ 4.0 Billion by 2028, exhibiting a growth rate (CAGR) of 11.7% during 2023-2028.
Anti-obesity drugs are intended to reduce or control weight and generally medically prescribed only in cases of morbid obesity. They help reduce cravings and control compulsive eating, especially for sweets and fatty, salty, and high-calorie food products. They can also provide independent health benefits, such as controlling blood pressure, harmful lipid levels, waist circumference, sugar levels and nonalcoholic fatty liver disease (NAFLD) and minimize the risk of major cardiovascular diseases (CVDs) and progression of diabetic kidney disease.
Anti-obesity drugs are intended to reduce or control weight and generally medically prescribed only in cases of morbid obesity. They help reduce cravings and control compulsive eating, especially for sweets and fatty, salty, and high-calorie food products. They can also provide independent health benefits, such as controlling blood pressure, harmful lipid levels, waist circumference, sugar levels and nonalcoholic fatty liver disease (NAFLD) and minimize the risk of major cardiovascular diseases (CVDs) and progression of diabetic kidney disease.
Anti-Obesity Drugs Market Trends:
Recent advances in anti-obesity drugs have enabled the potential of attaining clinically significant weight loss among individuals. This, in confluence with the widespread prevalence of obesity on account of sedentary lifestyles, represents one of the key factors creating a positive outlook for the market. In addition, obesity increases the risk of developing type 2 diabetes (T2D), cardiovascular diseases (CVD), and cancer of the esophagus, colon and rectum, liver, gallbladder, pancreas, and kidney. It can also result in numerous psychological, neurological, pulmonary, gastrointestinal, renal, musculoskeletal, and endocrine diseases. Besides this, sleep deprivation, circadian desynchronization, chronic stress, and the rising use of anti-epileptic and psychotropic drugs may further induce weight gain. This, coupled with the increasing number of approvals of anti-obesity medications (AOMs) that help regulate appetite and food cravings, is fueling the growth of the market. Apart from this, weight loss aids in improving the quality of life, mobility, daily function, and psychological well-being of individuals. This, along with the increasing health consciousness, thriving pharmaceutical industry, and the rising focus on the management of diseases closely integrated with excess body weight, is anticipated to stimulate the growth of the market.Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global anti-obesity drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug class, drug type and distribution channel.Breakup by Drug Class:
- Peripherally Acting Drugs
- Centrally Acting Drugs
Breakup by Drug Type:
- Prescription Drugs
- OTC Drugs
Breakup by Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Breakup by Region:
North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, Gelesis, GlaxoSmithKline plc, Merck & Co. Inc., Norgine B.V., Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals Inc., SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Vivus LLC.Key Questions Answered in This Report:
- What was the size of the global anti-obesity drugs market in 2022?
- What is the expected growth rate of the global anti-obesity drugs market during 2023-2028?
- What are the key factors driving the global anti-obesity drugs market?
- What has been the impact of COVID-19 on the global anti-obesity drugs market?
- What is the breakup of the global anti-obesity drugs market based on the drug class?
- What is the breakup of the global anti-obesity drugs market based on the drug type?
- What is the breakup of the global anti-obesity drugs market based on distribution channel?
- What are the key regions in the global anti-obesity drugs market?
- Who are the key players/companies in the global anti-obesity drugs market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Anti-Obesity Drugs Market
6 Market Breakup by Drug Class
7 Market Breakup by Drug Type
8 Market Breakup by Distribution Channel
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Boehringer Ingelheim International GmbH
- Currax Pharmaceuticals LLC
- Gelesis
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Norgine B.V.
- Novo Nordisk A/S
- Pfizer Inc.
- Rhythm Pharmaceuticals Inc.
- SHIONOGI & Co. Ltd.
- Takeda Pharmaceutical Company Limited and Vivus LLC
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 142 |
| Published | May 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 2 Billion |
| Forecasted Market Value ( USD | $ 4 Billion |
| Compound Annual Growth Rate | 12.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
